ACH · Accendra Health Inc/Va/
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (non-GAAP) non-GAAP | $118.46M | Six Months Ended June 30 | — |
| Free cash flow (non-GAAP) non-GAAP | -$27.11M | Six Months Ended June 30 | — |
| Net debt (non-GAAP) non-GAAP | $1.71B | June 30 | — |
GAAP → non-GAAP reconciliationGAAP Total debt, as reported (GAAP) 1.72B
-7.65M Cash and cash equivalents
= Net debt (non-GAAP) 1.71B
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACH
this stock
Accendra Health Inc/Va/
|
$52.73M | -83.9% | +3.1% | — | 11.6% |
|
MCK
Mckesson Corp
|
$101.04B | +11.6% | +3.1% | 23.3 | 2.5% |
|
COR
Cencora, Inc.
|
$57.74B | -6.8% | +9.3% | 22.5 | 2.3% |
|
CAH
Cardinal Health Inc
|
$52.08B | +13.4% | +14.2% | — | 2.9% |
|
HSIC
Henry Schein Inc
|
$9.63B | +11.4% | +5.9% | 25.2 | 6.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACH | -30.6% | -62.7% | -85.7% | -19.5% | -83.9% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -31.8% | -63.3% | -97.3% | -21.1% | -97.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.